Heart failure (HF) is a complex clinical syndrome characterized by inadequate cardiac function and a characteristic pattern of hemodynamic, renal, and neurohormonal responses leading to poor peripheral perfusion and impaired exercise tolerance. HF is among the leading causes of mortality and morbidity worldwide [@bib1]. Despite advances in medical therapy, the mortality for HF remains elevated, with overall rates of 35% to 40% at 1 year and 50% at 5 years [@bib2]. A significant proportion of HF patients, particularly those with severe left ventricular systolic dysfunction (LVSD), do not adequately respond to current medical therapy that may include beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, diuretics, and vasodilators [@bib3]. Despite many medication- and device-based improvements that have become guideline-based therapy, there is still a compelling clinical need to enhance cardiac function and outcomes in HF patients [@bib4], [@bib5].

Recombinant neuregulin (NRG)-1β is a naturally occurring growth factor that acts directly on cardiomyocytes and is being explored as a potential therapy for HF. NRG-1β regulates cardiac development through receptor tyrosine kinases in the epidermal growth factor receptor family, ERBB2-4 [@bib6]. The importance of this NRG-1/ERBB signaling pathway in the adult heart was demonstrated clinically when unexpectedly high rates of cardiotoxicity were observed in association with the chemotherapeutic agent trastuzumab, a monoclonal antibody that blocks the ERBB2 receptor [@bib7], [@bib8]. These clinical results and the ability of NRG-1β to activate cytoprotective mechanisms in cardiac myocytes has prompted investigations of its potential to enhance cardiac function in HF [@bib9], [@bib10]. Recent animal data support this notion. NRG-1β is released in response to ischemia, stress, and exercise, and is beneficial in animal models of cardiac injury by promoting restorative remodeling [@bib11], [@bib12], [@bib13]. A recombinant peptide representing the epidermal growth factor--like domain of NRG-1β (Neucardin, Zensun USA Inc., San Diego, California) has been studied in humans with stable chronic HF, where it improved hemodynamics acutely [@bib14] and when given by prolonged infusion over many days increased left ventricular (LV) systolic function [@bib15].

A larger full-length recombinant NRG-1β3 known as cimaglermin alfa (cimaglermin; also known as NRG-1β3, glial growth factor \[GGF\]-2) is also being examined as a possible treatment for HF [@bib12], [@bib13]. Although cimaglermin and Neucardin both act on ERBB receptor tyrosine kinases, the larger cimaglermin is distinct in structure, containing kringle and immunoglobulin-like domains [@bib16], [@bib17], and is manufactured in a mammalian cell expression system leading to complex glycosylation. The other domains of cimaglermin, beyond the epidermal growth factor--like domain, provide additional differences from the fragment including receptor binding, signaling, recycling, and extracellular matrix binding [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]. Cimaglermin improves cardiac function in rats and swine after myocardial infarction, even when administered as brief intravenous infusions twice per week [@bib11], [@bib12], [@bib13]. In addition to the HF models, cimaglermin has been shown to protect cardiomyocytes from toxicity both in vitro [@bib23], [@bib24] and in vivo [@bib25].

Given the preclinical promise of cimaglermin, we conducted a first-in-human, phase 1, randomized, placebo-controlled clinical trial to examine the safety and tolerability of single intravenous infusions of cimaglermin over a range of doses in human subjects with LVSD (left ventricular ejection fraction \[LVEF\] ≤40%) and HF.

Methods {#sec1}
=======

Human subjects {#sec1.1}
--------------

All patients had New York Heart Association (NYHA) functional class II to III HF and were maintained on an optimal medical regimen for at least 3 months before enrollment at Vanderbilt University Medical Center or Emory Heart and Vascular Center at Emory Saint Joseph's. All patients had an LVEF ≤40% on screening, no significant renal or liver disease, and an existing implantable cardioverter-defibrillator. Given the theoretical risk of administering a growth factor, patients with a history of cancer were excluded and an age-appropriate cancer screen was completed before enrollment. After informed consent, 40 patients with symptomatic HF were randomized (4:2) to cimaglermin or placebo in 7 ascending dose cohorts (0.007 mg/kg, 0.021 mg/kg, 0.063 mg/kg, 0.189 mg/kg, 0.378 mg/kg, 0.756 mg/kg, and 1.512 mg/kg). Each cohort of 6 patients was treated in 2 sequences. In sequence 1, 1 patient received placebo and 1 patient received cimaglermin. If no dose-limiting toxicities (DLTs) were observed, sequence 2 was initiated with 1 patient receiving placebo and 3 patients receiving cimaglermin. A dose escalation committee evaluated clinical, laboratory, and electrocardiographic safety before advancing to the next sequence or dose cohort ([Figure 1](#fig1){ref-type="fig"}). Patients were observed in a hospital for at least 48 h and then evaluated for adverse events (AEs) for 24 weeks after infusion with study visits at 1, 2, 4, and 12 weeks. AEs were graded using the Common Terminology Criteria for Adverse Events, version 4 [@bib26], [@bib27]. The trial was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. The study was performed at 2 institutions; the protocol was approved by the institutional review boards, and all participants gave written informed consent. The Trial Registration Identifier is [NCT01258387](https://clinicaltrials.gov/ct2/show/NCT01258387?term=NCT01258387&rank=1){#intref0010}.Figure 1Treatment AlgorithmDLT is defined as 1 of the following events deemed to be at least possibly related to study drug: 1) grade III toxicity or above (would encompass life-threatening events); 2) liver function abnormalities as defined in protocol; or 3) other events clinically judged to necessitate dose reductions. If a DLT occurs in the dose reduction step, the decision on whether to stop the study or to continue (reducing the dose by 1 additional dose level) will be made by sponsor and the principal investigator in consultation with the DSMB. DLT = dose-limiting toxicity; DSMB = Data Safety Monitoring Board; GGF = glial growth factor; PBO = placebo.

Drug administration {#sec1.2}
-------------------

Cimaglermin was produced under Good Manufacturing Practices in Chinese Hamster Ovary cells using animal-component-free media. The growth factor was purified to homogeneity using a series of standard chromatography steps. Patients received a 20- to 30-min intravenous bolus infusion of cimaglermin in 100 ml of dilution buffer or placebo (dilution buffer) without any premedication. Patients previously on strong CYP3A4 inhibitors had dose adjustments 2 weeks before receiving study drug, as cimaglermin was observed to affect CYP3A4 activity in vitro, which is being explored clinically ([NCT01944683](https://clinicaltrials.gov/ct2/show/NCT01944683?term=NCT01944683&rank=1){#intref0015}).

Study conduct {#sec1.3}
-------------

Two-dimensional echocardiography was performed at screening (day 0) and on days 8, 14, 28, and 90. LVEF, left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) were measured from orthogonal apical views using the Biplane Simpson's method [@bib28]. Ultrasound contrast was used for technically difficult studies according to the American Society of Echocardiography guidelines [@bib29]. All studies were reviewed in a blinded fashion by 2 experienced cardiologists with echocardiographic expertise. Blood sampling for safety assessments (hematology, biochemistry, and liver function), standard clinical and exploratory biomarkers, and assessment of antitherapeutic and neutralizing antibody formation were performed at similar time intervals. More frequent sampling was performed the first day for pharmacokinetics. Safety monitoring for rhythm disturbances included continuous telemetry, Holter monitoring, and electrocardiography at multiple time points during the initial hospital stay and at each subsequent visit. The final patient evaluation was at day 90 post dose, and patients were contacted by telephone at 6 months for status assessment. [Figure 2](#fig2){ref-type="fig"} summarizes protocol events.Figure 2Overview of Study Schema**(A)** The ascending doses of Cimaglermin were randomly assigned, and at the completion of each cohort (n = 6) a safety analysis was done by a DSMB before proceeding to the next dose level. **(B)** The initial 30-day screening period included assessment of LVEF, age-appropriate cancer screening, cardiology assessment for eligibility, and laboratory testing. **(C)** Eligible patients were dosed on day 0 with a single infusion of cimaglermin or placebo. Patients were observed in hospital on telemetry for at least 48 h, and multiple safety labs as well as electrocardiographic monitoring were performed. Patients returned on days 8, 14, 28, and 90 for laboratory, physical exam, echocardiography, and other safety assessments. AE = adverse event; DSMB = Data Safety Monitoring Board; LVEF = left ventricular ejection fraction; PK = pharmacokinetics.

Statistical methods {#sec1.4}
-------------------

Given the small size of each dose cohort, patients were pooled by dose levels into approximately equal groups (placebo, low-, and high-dose groups) in a post-hoc manner. The low-dose group (n = 12) comprises the 0.007-mg/kg, 0.021-mg/kg, 0.063-mg/kg cohorts and the high-dose group (n=15) comprises the 0.189-mg/kg, 0.378-mg/kg, 0.75-mg/kg and 1.5-mg/kg groups. Additionally, the initial dose levels were anticipated to be sub-therapeutic based on preclinical studies and were included to ensure safety in a first-in-human study. Descriptive statistics were used to summarize the data by treatment group. Continuous variables were summarized using descriptive statistics such as mean and standard error; categorical variables were summarized using frequencies and percentages. Additional exploratory analyses were performed on echocardiography measurements of LVEF to evaluate the treatment effects of cimaglermin compared with placebo. LVEF was pre-defined as the first exploratory efficacy measure. Treatment differences were considered statistically significant if the p values were \<0.05. To show the overall treatment effect over time, the area under the curve (AUC) as a summary score was evaluated. The derived AUC scores were analyzed via the analysis of covariance model, with treatment group as a factor and corresponding baseline measure as a covariate. Dunnett's test was used to adjust for the experiment-wise type I error rate. A mixed model repeated measures was also conducted to show the time profile. The treatment group, corresponding baseline measure, visit, and treatment by visit interaction effects were included in the mixed model repeated measures model. The unstructured variance-covariance and Kenward-Roger degree of freedom adjustment were used. Nominal p values were presented to show the entire clinical picture. The relationship of change in LVEF with dose was tested using the Jonckheere-Terpstra test. All statistics were performed with SAS version 9.4 software (SAS Institute, Cary, North Carolina).

Results {#sec2}
=======

Forty patients of a planned 42 (7 cohorts of 6 patients) were enrolled as study recruitment was suspended following a serious adverse event (SAE) in the 40th patient. Eighty-three percent (n = 33) of patients enrolled were male, 60% had NYHA functional class II, and 40% had NYHA functional class III symptoms. Seventy-three percent (n = 29) had known significant coronary disease and established ischemic HF. The mean age was 57.4 ± 9.8 years. Other patient characteristics and concomitant medications during the study period are shown in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. Patients were maintained on optimal medical therapy for at least 3 months before enrollment in the trial ([Table 2](#tbl2){ref-type="table"}). Given the small size of the study, the demographics were relatively well matched. There were no clinically significant treatment effects of a single dose of cimaglermin on hematologic, electrical, or the majority of biochemical safety laboratory testing performed, with the exception of the DLT described in more detail below.Table 1Characteristics of the Patients at BaselineAll (N = 40)Placebo (n = 13)CimaglerminLow Dose (n = 12)High Dose (n = 15)Age, yrs57.4 ± 9.854.7 ± 13.255.8 ± 7.860.9 ± 7.0Male33 (83)12 (92)8 (67)13 (87)Race African American4 (10)1 (8)2 (17)1 (7) Caucasian36 (90)12 (92)10 (83)14 (93)Weight, kg93.8 ± 21.5102.2 ± 23.189.0 ± 21.890.4 ± 17.8Duration of HF (months)95.0 ± 94.995.0 ± 63.569.6 ± 59.9114.5 ± 134.0Ischemic/nonischemic Ischemic29 (73)9 (69)9 (75)11 (73) Nonischemic11 (28)4 (31)3 (25)4 (27)NYHA functional class II24 (60)7 (54)7 (58)10 (67) III16 (40)6 (46)5 (42)5 (33)Baseline LVEF (%)27.5 ± 1.329.2 ± 2.927.5 ± 1.926.0 ± 1.9[^1][^2]Table 2Concomitant Medications at BaselineMedication ClassAll (N = 40)Placebo (n = 13)CimaglerminLow Dose (n = 12)High Dose (n = 15)Beta-blocker39 (98)12 (92)12 (100)15 (100)ACEI or ARB32 (80)10 (77)11 (92)11 (73)Diuretic35 (88)10 (77)11 (92)14 (93)MRA27 (68)5 (38)8 (67)14 (93)Statin or other cholesterol-lowering34 (85)11 (85)10 (83)13 (87)Aspirin28 (70)10 (77)10 (83)8 (53)Other antiplatelet16 (40)4 (31)4 (33)8 (53)Anticoagulant14 (35)6 (46)4 (33)4 (27)Antiarrhythmic10 (25)5 (38)2 (17)3 (20)Digoxin18 (45)5 (38)9 (75)4 (27)Vasodilator34 (85)11 (85)10 (83)13 (87)[^3][^4]

There were no acute AEs leading to termination of drug infusion. There were no study withdrawals due to AEs. The most frequently observed treatment-emergent adverse events (TEAEs) are shown in [Table 3](#tbl3){ref-type="table"}. A TEAE was defined as an event with a date of onset, or worsening, on or after the start of double-blind treatment and no more than 28 days from the start date of double-blind treatment. A higher percentage of patients receiving cimaglermin had symptoms of a headache (9 of 27, 33% vs. 0 of 13, 0%) as well as nausea compared with placebo (7 of 27, 26% vs. 2 of 13, 16%). The summary of serious AEs is shown in [Table 3](#tbl3){ref-type="table"}. Four patients, each in a different cohort (levels 1, 2, 4, and 7), had 1 serious AE. The serious AEs occurred in 2 of 12 patients (17%) of the total low-dose group (cohorts 1 to 3) and 2 of 15 (13%) of the total high-dose group (cohorts 4 to 7); they were viral infection requiring admission (cohort 1; 0.007 mg/kg); angina requiring nitroglycerin treatment (cohort 2; 0.021 mg/kg); worsening HF requiring admission (cohort 4; 0.189 mg/kg); and transient liver transaminase elevation and hyperbilirubinemia meeting the criteria of Hy's law (cohort 7; 1.512 mg/kg) [@bib30]. These events, with the exception of viral infection, were considered by the investigator to be possibly or probably related to the investigational product. All of the patients recovered with observation and medical treatment and without longer-term sequelae. No serious AEs were reported in the following treatment groups: placebo, cohort 3 (0.063 mg/kg), cohort 5 (0.378 mg/kg), and cohort 6 (0.756 mg/kg).Table 3Treatment-Emergent Adverse EventsPlacebo (n = 13)CimaglerminLow Dose (n = 12)High Dose (n = 15)TEAEs Headache05 (42)4 (27) Nausea2 (15)1 (8)6 (40) Fatigue1 (8)2 (17)4 (27) Diarrhea01 (8)4 (27) Cough01 (8)3 (20) Dyspnea02 (17)1 (7) Elevated GGT003 (20) Hypotension003 (20) Abdominal distension002 (13) Elevated BNP002 (13) Decreased appetite002 (13) Dysgeusia002 (13) Nasal congestion02 (17)0 Upper-respiratory tract symptoms002 (13)Severe TEAEs[∗](#tbl3fnlowast){ref-type="table-fn"} Angina pectoris01 (8)0 Congestive heart failure001 (7) Hy's law case001 (7) Viral infection01 (8)0[^5][^6][^7]

The transient liver transaminase elevation and hyperbilirubinemia that occurred in 1 patient who received 1.5 mg/kg of cimaglermin, the highest planned dose, defined a DLT. This patient presented to a local emergency department approximately 48 h after release from the study hospital with abdominal pain and was found to have elevated liver transaminases and bilirubin. Normalization of the liver enzymes and bilirubin, along with resolution of abdominal pain, occurred over 96 h under careful observation and symptom management. At the next observed time point of 14 days after dosing, the liver enzymes returned to baseline values.

All study patients had age-appropriate cancer screenings that were negative before enrollment. One patient with intermittent microscopic hematuria before enrollment was ultimately diagnosed with bladder cancer 3 months after receiving study drug. External review of the details of this case by an expert urogenital oncologist determined that this was not likely related to study drug based upon the natural history and risk factors for the development of bladder cancers.

Serial echocardiogram measurements were measured and evaluated in a blinded fashion. The results of LVEF, LVEDV, LVESV, heart rate, and blood pressure are summarized in [Table 4](#tbl4){ref-type="table"}, and the primary exploratory efficacy measure of LVEF is displayed in [Figure 3](#fig3){ref-type="fig"} with additional data provided in the [Supplemental Figure](#appsec1){ref-type="sec"}. There was a sustained, dose-related increase in LVEF through 90 days after dosing in the high-dose cimaglermin group when compared with the placebo group, (p \< 0.01) ([Figures 3](#fig3){ref-type="fig"} and [4B](#fig4){ref-type="fig"}). There was no change in LVEF in placebo-treated patients. In low-dose cimaglermin treated patients, there was a small nonsignificant increase in LVEF which returned to baseline by 90 days. In the high-dose cimaglermin treated patients, there was a mean increase of 9 absolute percentage units of LVEF, and changes reached their maximum increase at day 28 ([Figure 3](#fig3){ref-type="fig"}) and were sustained throughout the duration of the safety measurements. Additionally, at the 90-day time point there was a nonsignificant trend toward a reduction in LVESV, especially at the higher doses (-23.2 ml compared with baseline). The AUC for absolute changes in LVEF during the 90 days of observation by dose groups is shown in [Figures 4A and 4B](#fig4){ref-type="fig"}; the high-dose group (0.189-mg/kg, 0.378-mg/kg, 0.756-mg/kg, and 1.512-mg/kg cohorts) was significantly increased compared with placebo and low-dose (0.007-mg/kg, 0.021-mg/kg, and 0.063-mg/kg cohorts) treated patients (p \< 0.01). Even when censoring the data from the highest dose cohort with the DLT (cohort 7, 1.512 mg/kg), the sustained increases in LVEF persist over 90 days ([Figures 3](#fig3){ref-type="fig"} and [4A](#fig4){ref-type="fig"}). When mean changes in LVEF over 90 days are plotted for each individual dose cohort ([Figure 4B](#fig4){ref-type="fig"}), there is a significant correlation between dose and LVEF change (R^2^ = 0.6735; p = 0.0012).Table 4Cardiac Parameters and BiomarkersDays Post Treatment08142890Parameters LVEF Placebo29.2 ± 10.528.4 ± 6.028.1 ± 7.828.9 ± 6.831.1 ± 7.4 Low dose27.5 ± 6.631.6 ± 8.128.2 ± 9.331.0 ± 8.026.8 ± 6.4 High dose26.0 ± 7.529.0 ± 7.932.2 ± 11.634.9 ± 7.334.5 ± 8.0 LVESV Placebo195.5 ± 120.7194.6 ± 86.0176.5 ± 82.3192.1 ± 91.0182.9 ± 95.8 Low dose164.7 ± 107.3161.2 ± 98.6161.7 ± 91.8167.8 ± 103.1175.9 ± 102.7 High dose151.0 ± 74.2139.5 ± 64.1126.9 ± 67.3131.1 ± 73.4127.8 ± 85.2 LVEDV Placebo284.6 ± 112.7269.7 ± 109.1243.0 ± 94.8258.8 ± 95.1258.9 ± 77.6 Low dose221.2 ± 124.0227.4 ± 115.7217.4 ± 99.3235.1 ± 116.3235.7 ± 119.9 High dose202.8 ± 91.3198.9 ± 80.8180.0 ± 82.9196.7 ± 100.3184.2 ± 109.1 HR Placebo67.9 ± 8.672.5 ± 11.1ND71.0 ± 10.6ND Low dose69.9 ± 6.573.4 ± 9.1ND69.9 ± 10.2ND High dose68.4 ± 13.267.5 ± 9.6ND69.6 ± 9.9ND MAP Placebo80.4 ± 6.982.2 ± 6.4ND84.5 ± 5.2ND Low dose79.6 ± 10.986.1 ± 13.5ND79.0 ± 10.2ND High dose73.1 ± 7.589.8 ± 9.7ND87.0 ± 10.0ND SBP Placebo119.6 ± 12.0109.6 ± 8.6ND112.1 ± 10.4ND Low dose115.9 ± 18.8116.8 ± 20.8ND107.9 ± 12.9ND High dose114.2 ± 14.3117.1 ± 11.4ND115.5 ± 11.8ND DBP Placebo71.1 ± 4.768.5 ± 7.1ND70.6 ± 4.3ND Low dose65.9 ± 9.170.8 ± 12.9ND64.5 ± 10.4ND High dose70.9 ± 10.176.1 ± 9.7ND72.7 ± 10.8NDBiomarkers BNP (pg/ML) Placebo230 (108, 299; 191)202 (89, 317; 228)ND177 (115, 237; 122)ND Low dose279 (140, 432; 292)332 (188, 447; 258)ND267 (116, 405; 289)ND High dose108 (80, 301; 221)230 (185, 619; 434)ND162 (74, 342; 268)ND NT-proBNP (fmol/ML) Placebo898 (527, 1,495; 968)877 (536, 1,467; 931)ND800 (564, 1,044; 480)ND Low dose831 (513, 947; 434)843 (658, 937; 279)ND910 (508, 1,161; 653)ND High dose552 (310, 1,134; 824)1193 (702, 1,598; 896)ND653 (328, 1,194; 866)ND Tn-I (ng/l) Placebo20 (20, 30; 10)20 (10, 30; 20)ND10 (10, 30; 20)ND Low dose10 (10, 10; 0)10 (10, 15; 5)ND10 (10, 10; 0)ND High dose10 (10, 20; 10)10 (10, 25; 15)ND10 (10, 30; 20)ND[^8][^9]Figure 3Mean Absolute Change in LVEF After DosingThe mean absolute change in LVEF from baseline for the patients in the placebo, pooled low-dose, and high-dose groups are displayed over 90 days. The **dashed line** represents the high-dose group with cohort 7 (highest dose 1.5 mg/kg, with DLT) data included. Since this dose will no longer be developed clinically, the **solid blue line** represents the data without this cohort. There was a significant increase in LVEF at 30 days between the high groups compared with placebo (p \< 0.01). At 90 days, only the highest dose group showed a significant increase compared with the placebo group (p \< 0.01). Abbreviations as in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}.Figure 4Mean AUC for Absolute Change in LVEF Over 90 Days**(A)** The mean AUC for change in LVEF over 90 days in all patients is displayed for the placebo **(grey),** low-dose **(green),** and high-dose **(blue)** groups (with the **lighter portion** in the high-dose group including cohort 7). The high-dose group had a significantly greater increase in LVEF when compared with the low-dose or placebo groups. This was significant whether the highest dose (1.5 mg/kg) cohort was included **(lighter blue bar)** or not **(darker blue bar)** (p \< 0.01). **(B)** The mean AUC for change in LVEF over 90 days in all patients is displayed for each individual dose cohorts and plotted on a logarithmic scale. The individual dose cohorts that were grouped into the placebo, low and high dose are color coded as in **A**. R^2^ = 0.6735. The Jonckheere-Terpstra test showed a significant relationship between dose and change in LVEF AUC 0-90 (p = 0.0012). AUC = area under the curve; LVEF = left ventricular ejection fraction.

Discussion {#sec3}
==========

In this first-in-human study of cimaglermin, a dose range for future studies was identified. There were no discontinuations based on AEs. Overall, the most commonly experienced TEAEs were nausea (7 of 27, 26%) and headache (9 of 27, 33%) that were temporally associated with study drug exposure. Nausea occurred in some patients who received a placebo infusion (2 of 13, 15%). A DLT of transient liver transaminase elevation and hyperbilirubinemia was observed in 1 patient at the highest planned dose. Some liver enzyme changes were anticipated at higher doses based on preclinical toxicology studies. The liver transaminase elevation and hyperbilirubinemia observed, although it met criteria for Hy's law, was temporary and not associated with any long-term sequelae for the subject.

In addition to these safety findings, the results of the study appear to indicate that a single infusion of cimaglermin may lead to an increase in LVEF, and this effect seemed to persist for up to 90 days in the high-dose group. The dose levels of cimaglermin examined in this study are within the range of doses used in animal studies and shown to enhance cardiac function [@bib11], [@bib13]. Preclinical studies indicate that repeated dosing is necessary for sustained improvement in heart function. Further clinical studies are required to determine the optimal dose and dosing interval for this agent, as well as the effect of repeated dosing on LVEF.

The exact mechanism for such a potentially enduring effect of cimaglermin on LV systolic function is not known, but certainly enhancement of cardiac repair processes is one hypothesis that is plausible given the known actions of NRG-1β stimulation in cardiac cells [@bib31]. The preclinical work leading up to this study used multiple doses of intravenous cimaglermin over weeks in animals not on background neurohormonal blockade. There may be marked species differences in the duration of effect. Alternatively, the combined effects of cimaglermin on myocyte survival, fibrosis, and inflammation, in the context of optimal medical therapy with neurohormonal blockade, may provide a possible explanation for this difference between preclinical and clinical data [@bib32].

The most frequent side effects, headache and nausea, are similar to what has been reported with Neucardin, a recombinant protein based upon only the epidermal growth factor domain fragment of NRG-1β [@bib30]. Vomiting was observed in preclinical study of cimaglermin in swine [@bib11], and thus it appears that gastrointestinal side effects might be a class effect. These symptoms were easily managed with standard antiemetics, but the mechanism for this is not clear at this time. Although infrequent compared with other AEs, transient liver transaminase elevation and hyperbilirubinemia is the most concerning AE of a single infusion. It will be important to understand the nature of this potential toxicity so the relative risks and benefits of cimaglermin for the treatment of HF can be determined.

A theoretical concern for the clinical development of neuregulins as therapeutic agents is the potential for growth effects on pre-existing ERBB-driven cancers. In this initial study, we screened patients in an attempt to exclude anyone with a pre-existing tumor. However, 1 patient with multiple risk factors for bladder cancer and pre-existing microscopic hematuria developed gross hematuria 3 months after receiving cimaglermin. This patient was found to have superficial bladder carcinoma that has since been successfully treated with cystoscopy-based therapy with no evidence of disease recurrence after more than 1 year. An expert urogenital oncologist adjudicated this event to be unrelated to study drug based on the pre-existing hematuria and the expected growth rates of bladder carcinomas following toxin exposure.

The safety, tolerability, and cardiac activity of a range of doses identified in this study support further work with cimaglermin in chronic HF. At the time of this submission, a second trial is under way to assess further the safety, tolerability, drug-drug interactions, and potential efficacy of cimaglermin ([NCT01944683](https://clinicaltrials.gov/ct2/show/NCT01944683?term=NCT01944683&rank=1){#intref0020}). Although the etiology of HF was not part of the inclusion criteria for the current study, we were careful to make sure that this was a relatively homogeneous HF population with respect to other diseases that might impact safety, such as renal insufficiency, liver function abnormalities, and insulin-dependent diabetes mellitus. The study subjects were all symptomatic with NYHA functional class II to III, American Heart Association stage C patients, and despite being on stable optimal medical therapy for a minimum of 3 months ([Table 1](#tbl1){ref-type="table"}), showed increases in LVEF following a single infusion of cimaglermin.

Study limitations {#sec3.1}
-----------------

The limitations of this study, by the nature of the design, is that it is a small study intended to document safety. Because it was a first-in-man dose-escalating study, the initial doses in humans were known to be subtherapeutic in animal studies. Similarly, there was only a single infusion as opposed to multiple doses for the same reason to maximize patient safety. Lastly, the relatively short time for follow-up is sufficient to detect potential changes in cardiodynamics but not long enough to establish a difference in major clinical events.

Conclusions {#sec4}
===========

A single intravenous dose of cimaglermin was tolerated in the majority of patients with systolic LV dysfunction and HF in a first-in-human safety study. The most common AEs, occurring more frequently at the higher doses, were headache (33%) followed by nausea (27%). Serious TEAEs were uncommon, and the DLT at the highest planned dose (1.5 mg/kg) was a case of transient liver transaminase elevation and hyperbilirubinemia meeting U.S. Food and Drug Administration guidance for drug-induced liver injury (Hy's law) that resolved completely within 2 weeks. There was a suggestion of improvement in LV function based on a sustained increase in LVEF over 90 days at the higher doses of cimaglermin. These findings support continued clinical development of the investigational drug cimaglermin, including further safety evaluations and detailing the potential improvement on clinical HF outcome measures.Perspectives**COMPETENCY IN MEDICAL KNOWLEDGE:** In patients with symptomatic HF due to LVSD on optimal medical therapy, a single intravenous dose of cimaglermin appears to result in a dose-dependent improvement in LVEF for up to 90 days. This therapy was associated with nausea and headache, and at a higher dose there was transient liver transaminase elevation and hyperbilirubinemia. The implications of toxicity must be balanced with potential therapeutic benefit.**TRANSLATIONAL OUTLOOK:** Larger prospective randomized studies are needed with carefully selected doses, as well as repeat dosing, to establish patient safety and improvement in ventricular remodeling, functional status, and other measures of cardiac function.

Appendix {#appsec1}
========
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[^1]: Values are mean ± SD or n (%).

[^2]: HF = heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

[^3]: Values are n (%). Patients previously on strong CYP3A/4 inhibitors had dose adjustments 2 weeks prior to receiving study drug, as cimaglermin was observed to affect CYP3A4 activity in vitro, which is being explored clinically.

[^4]: ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; MRA = mineralocorticoid receptor antagonist.

[^5]: Values are n (%).

[^6]: BNP = B-type natriuretic peptide; GGT = gamma-glutamyl transferase; TEAE = treatment-emergent adverse event.

[^7]: Common Terminology Criteria for Adverse Events grade 3 or higher.

[^8]: Values are mean ± SD or median (25th, 75th; interquartile range).

[^9]: DBP = diastolic blood pressure; HR = heart rate; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; MAP = mean arterial pressure; ND = not done; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SBP = systolic blood pressure; Tn-I = troponin I.
